Gamlen Tablet Press produces model data
Used to demonstrate the use of statistical methodologies of Principal Components Analysis and Design of Experiments.
Gamlen R-series tablet presses have been used to demonstrate the use of statistical methodologies of Principal Components Analysis (PCA) and Design of Experiments (DoE) in a workshop on understanding and optimising chemical processes.
Delivered by the Industrial Statistics Research Unit (ISRU), Newcastle University and the Department of Chemistry, Durham University, the Gamlen R-series (formally the GTP-1) was used during practical sessions to produce tabletability data.
Professor Patrick Steel, Durham University, explains: “As part of the course we conducted a laboratory experiment. One of the problems in creating the course is designing an experiment that will deliver reproducible results so that the students can generate models from the data.
We were keen to choose a chemistry orientated experiment — with tablet making there are a number of variables that can be controlled such as the speed of the press, the composition of the tablet and the compaction force. These are all variables that we could adjust fairly easily in the lab experiment. During trialling, we quickly found that the Gamlen Tablet Press generated very consistent results and allowed control of variables which made the Gamlen R-series an ideal tool to teach the important course principles.
Experiments were conducted repeatedly over the two consecutive days of the course and were found to generate the same data. To get our course objectives across, it was imperative that we could rely on the experiment to work and the Gamlen Tablet Press gave us that reproducibility. If errors occurred, something had gone wrong in the experiment itsel; i.e., errors were errors — not random noise in the data. This was important as it supported the material we were teaching.”
Gamlen R-series tablet presses are easy to use, with novice users requiring as little as 30 minutes training to be able to control the basic functions of the instruments. Ideal for the academic research market, Gamlen R-series machines are entirely computer-controlled, portable, laboratory instruments that enable understanding and experimentation with the relationship between the properties of substances, the composition of a formulation and the manufacturing process.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance